{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T17:12:25Z","timestamp":1769879545440,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s40273-023-01288-1","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T07:02:39Z","timestamp":1686812559000},"page":"1263-1274","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Modeling Monthly Migraine-Day Distributions Using Longitudinal Regression Models and Linking Quality of Life to Inform Cost-Effectiveness Analysis: A Case Study of Fremanezumab in Japanese-Korean Migraine Patients"],"prefix":"10.1007","volume":"41","author":[{"given":"Xinyu","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Yamato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitsugu","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef J.","family":"Paris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth F. P.","family":"Peterse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5248-1676","authenticated-orcid":false,"given":"Martijn J. H. G.","family":"Simons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Bennison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"key":"1288_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12874-019-0664-5","volume":"19","author":"GL Di Tanna","year":"2019","unstructured":"Di Tanna GL, et al. Migraine day frequency in migraine prevention: longitudinal modelling approaches. BMC Med Res Methodol. 2019;19:20. https:\/\/doi.org\/10.1186\/s12874-019-0664-5.","journal-title":"BMC Med Res Methodol"},{"key":"1288_CR2","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12955-019-1242-6","volume":"17","author":"GL Di Tanna","year":"2019","unstructured":"Di Tanna GL, et al. Longitudinal assessment of utilities in patients with migraine: an analysis of erenumab randomized controlled trials. Health Qual Life Outcomes. 2019;17:171. https:\/\/doi.org\/10.1186\/s12955-019-1242-6.","journal-title":"Health Qual Life Outcomes"},{"key":"1288_CR3","doi-asserted-by":"publisher","first-page":"A732","DOI":"10.1016\/j.jval.2017.08.1997","volume":"20","author":"RB Lipton","year":"2017","unstructured":"Lipton RB, Brennan A, Palmer S, Jansen JP, Hatswell AJ, Porter JK, Di Tanna GL, Villa G, Shah N, Sapra S. Novel biologics versus conventional preventive therapies in migraine: a framework for economic evaluation. Value Health. 2017;20:A732. https:\/\/doi.org\/10.1016\/j.jval.2017.08.1997.","journal-title":"Value Health"},{"key":"1288_CR4","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11916-011-0233-z","volume":"16","author":"Z Katsarava","year":"2012","unstructured":"Katsarava Z, Buse DC, Manack AN, Lipton RB. Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep. 2012;16:86\u201392. https:\/\/doi.org\/10.1007\/s11916-011-0233-z.","journal-title":"Curr Pain Headache Rep"},{"key":"1288_CR5","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1111\/j.1526-4610.2012.02223.x","volume":"52","author":"DC Buse","year":"2012","unstructured":"Buse DC, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache. 2012;52:1456\u201370. https:\/\/doi.org\/10.1111\/j.1526-4610.2012.02223.x.","journal-title":"Headache"},{"key":"1288_CR6","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 2018;319:1999\u20132008. https:\/\/doi.org\/10.1001\/jama.2018.4853.","journal-title":"JAMA"},{"key":"1288_CR7","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377:2113\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1709038.","journal-title":"N Engl J Med"},{"key":"1288_CR8","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019;394:1030\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(19)31946-4.","journal-title":"Lancet"},{"key":"1288_CR9","doi-asserted-by":"publisher","first-page":"333102422114631","DOI":"10.1177\/03331024221146315","volume":"43","author":"MJ Lee","year":"2023","unstructured":"Lee MJ, Al-Karagholi MA, Reuter U. New migraine prophylactic drugs: current evidence and practical suggestions for non-responders to prior therapy. Cephalalgia. 2023;43:3331024221146315. https:\/\/doi.org\/10.1177\/03331024221146315.","journal-title":"Cephalalgia"},{"key":"1288_CR10","doi-asserted-by":"publisher","first-page":"333102423115216","DOI":"10.1177\/03331024231152169","volume":"43","author":"R Messina","year":"2023","unstructured":"Messina R, et al. Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: a systematic review and network meta-analysis. Cephalalgia. 2023;43:3331024231152169. https:\/\/doi.org\/10.1177\/03331024231152169.","journal-title":"Cephalalgia"},{"key":"1288_CR11","unstructured":"National institute for Health and Care Excellence. Fremanezumab for preventing migraine. (2020)."},{"key":"1288_CR12","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3111\/13696998.2013.802694","volume":"16","author":"AJ Batty","year":"2013","unstructured":"Batty AJ, et al. The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK. J Med Econ. 2013;16:877\u201387. https:\/\/doi.org\/10.3111\/13696998.2013.802694.","journal-title":"J Med Econ"},{"key":"1288_CR13","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1111\/j.1526-4610.2005.05182.x","volume":"45","author":"JS Brown","year":"2005","unstructured":"Brown JS, et al. Cost-effectiveness of topiramate in migraine prevention: results from a pharmacoeconomic model of topiramate treatment. Headache. 2005;45:1012\u201322. https:\/\/doi.org\/10.1111\/j.1526-4610.2005.05182.x.","journal-title":"Headache"},{"key":"1288_CR14","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2165\/11531180-000000000-00000","volume":"24","author":"J Yu","year":"2010","unstructured":"Yu J, Smith KJ, Brixner DI. Cost effectiveness of pharmacotherapy for the prevention of migraine: a Markov model application. CNS Drugs. 2010;24:695\u2013712. https:\/\/doi.org\/10.2165\/11531180-000000000-00000.","journal-title":"CNS Drugs"},{"key":"1288_CR15","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/13696998.2018.1457533","volume":"21","author":"RB Lipton","year":"2018","unstructured":"Lipton RB, et al. Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. J Med Econ. 2018;21:666\u201375. https:\/\/doi.org\/10.1080\/13696998.2018.1457533.","journal-title":"J Med Econ"},{"key":"1288_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/sim.2331","volume":"25","author":"P Royston","year":"2006","unstructured":"Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med. 2006;25:127\u201341. https:\/\/doi.org\/10.1002\/sim.2331.","journal-title":"Stat Med"},{"key":"1288_CR17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s41669-018-0105-0","volume":"3","author":"JK Porter","year":"2019","unstructured":"Porter JK, Di Tanna GL, Lipton RB, Sapra S, Villa G. Costs of acute headache medication use and productivity losses among patients with migraine: insights from three randomized controlled trials. Pharmacoecon Open. 2019;3:411\u20137. https:\/\/doi.org\/10.1007\/s41669-018-0105-0.","journal-title":"Pharmacoecon Open"},{"key":"1288_CR18","doi-asserted-by":"publisher","first-page":"A733","DOI":"10.1016\/j.jval.2017.08.2004","volume":"20","author":"J Porter","year":"2017","unstructured":"Porter J. Parametric modelling of migraine day frequency in migraine prevention: a case study of erenumab clinical trial data. Value Health. 2017;20:A733.","journal-title":"Value Health"},{"key":"1288_CR19","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/head.14169","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, et al. Efficacy and safety of fremanezumab for chronic migraine prevention: multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache. 2021;61:1092\u2013101. https:\/\/doi.org\/10.1111\/head.14169.","journal-title":"Headache"},{"key":"1288_CR20","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/head.14178","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, et al. Efficacy and safety of fremanezumab for episodic migraine prevention: multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache. 2021;61:1102\u201311. https:\/\/doi.org\/10.1111\/head.14178.","journal-title":"Headache"},{"key":"1288_CR21","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s40264-021-01119-2","volume":"44","author":"F Sakai","year":"2021","unstructured":"Sakai F, et al. Long-term safety and tolerability of fremanezumab for migraine preventive treatment in Japanese outpatients: a multicenter, randomized, open-label study. Drug Saf. 2021;44:1355\u201364. https:\/\/doi.org\/10.1007\/s40264-021-01119-2.","journal-title":"Drug Saf"},{"key":"1288_CR22","unstructured":"EuroQolResearchFoundation. EQ-5D-5L User Guide. Version 3.0. September. (2019)."},{"key":"1288_CR23","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s11136-012-0230-7","volume":"22","author":"R Rendas-Baum","year":"2013","unstructured":"Rendas-Baum R, Bloudek LM, Maglinte GA, Varon SF. The psychometric properties of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) in chronic migraine patients. Qual Life Res. 2013;22:1123\u201333. https:\/\/doi.org\/10.1007\/s11136-012-0230-7.","journal-title":"Qual Life Res"},{"key":"1288_CR24","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.jval.2016.03.1834","volume":"19","author":"T Shiroiwa","year":"2016","unstructured":"Shiroiwa T, et al. Comparison of value set based on DCE and\/or TTO data: scoring for EQ-5D-5L health states in Japan. Value Health. 2016;19:648\u201354. https:\/\/doi.org\/10.1016\/j.jval.2016.03.1834.","journal-title":"Value Health"},{"key":"1288_CR25","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jval.2011.12.007","volume":"15","author":"PJ Gillard","year":"2012","unstructured":"Gillard PJ, Devine B, Varon SF, Liu L, Sullivan SD. Mapping from disease-specific measures to health-state utility values in individuals with migraine. Value Health. 2012;15:485\u201394. https:\/\/doi.org\/10.1016\/j.jval.2011.12.007.","journal-title":"Value Health"},{"key":"1288_CR26","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/13696998.2020.1716775","volume":"23","author":"I Kamae","year":"2020","unstructured":"Kamae I, Thwaites R, Hamada A, Fernandez JL. Health technology assessment in Japan: a work in progress. J Med Econ. 2020;23:317\u201322. https:\/\/doi.org\/10.1080\/13696998.2020.1716775.","journal-title":"J Med Econ"},{"key":"1288_CR27","unstructured":"The National Insitute for Health and Care Excellence. Erenumab for preventing migraine (TA682). https:\/\/www.nice.org.uk\/guidance\/ta682 (2021)."},{"key":"1288_CR28","first-page":"507","volume":"54","author":"RA Rigby","year":"2005","unstructured":"Rigby RA, Stasinopoulos DM. Generalized additive models for location, scale and shape. Appl Stat. 2005;54:507\u201354.","journal-title":"Appl Stat"},{"key":"1288_CR29","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.4794","volume":"6","author":"XA Harrison","year":"2018","unstructured":"Harrison XA, et al. A brief introduction to mixed effects modelling and multi-model inference in ecology. PeerJ. 2018;6: e4794. https:\/\/doi.org\/10.7717\/peerj.4794.","journal-title":"PeerJ"},{"key":"1288_CR30","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/978-1-4612-1694-0_15","volume-title":"Selected Papers of hirotugu akaike","author":"H Akaike","year":"1998","unstructured":"Akaike H. In: Parzen E, Tanabe K, Kitagawa G, editors. Selected Papers of hirotugu akaike. New York: Springer; 1998. p. 199\u2013213."},{"key":"1288_CR31","doi-asserted-by":"publisher","first-page":"144","DOI":"10.6000\/1929-6029.2013.02.02.08","volume":"2","author":"G Grover","year":"2013","unstructured":"Grover G, Gadpayle AK, Swain PK. A multistate markov model based on CD4 cell count for HIV\/AIDS patients on antiretroviral therapy (ART). Int J Stat Med Res. 2013;2:144\u201351.","journal-title":"Int J Stat Med Res"},{"key":"1288_CR32","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1177\/0272989x15610781","volume":"37","author":"A Exuzides","year":"2017","unstructured":"Exuzides A, et al. Statistical modeling of disease progression for chronic obstructive pulmonary disease using data from the ECLIPSE study. Med Decis Making. 2017;37:453\u201368. https:\/\/doi.org\/10.1177\/0272989x15610781.","journal-title":"Med Decis Making"},{"key":"1288_CR33","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jval.2018.10.008","volume":"22","author":"M Hoogendoorn","year":"2019","unstructured":"Hoogendoorn M, Corro Ramos I, Baldwin M, Gonzalez-Rojas Guix N, Rutten-van M\u00f6lken M. Broadening the perspective of cost-effectiveness modeling in chronic obstructive pulmonary disease: a new patient-level simulation model suitable to evaluate stratified medicine. Value Health. 2019;22:313\u201321. https:\/\/doi.org\/10.1016\/j.jval.2018.10.008.","journal-title":"Value Health"},{"key":"1288_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02369-x","author":"LC Powell","year":"2022","unstructured":"Powell LC, et al. Health state utility mapping of rimegepant for the preventive treatment of migraine: double-blind treatment phase and open label extension (BHV3000-305). Adv Ther. 2022. https:\/\/doi.org\/10.1007\/s12325-022-02369-x.","journal-title":"Adv Ther"},{"key":"1288_CR35","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s40261-021-01115-5","volume":"42","author":"SJ Tepper","year":"2022","unstructured":"Tepper SJ, et al. Effects of galcanezumab on health-related quality of life and disability in patients with previous failure of 2\u20134 migraine preventive medication categories: results from a phase IIIb randomized, placebo-controlled, multicenter clinical trial (CONQUER). Clin Drug Investig. 2022;42:263\u201375. https:\/\/doi.org\/10.1007\/s40261-021-01115-5.","journal-title":"Clin Drug Investig"},{"key":"1288_CR36","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s12874-022-01762-y","volume":"22","author":"K Khan","year":"2022","unstructured":"Khan K, et al. Mapping between headache specific and generic preference-based health-related quality of life measures. BMC Med Res Methodol. 2022;22:277. https:\/\/doi.org\/10.1186\/s12874-022-01762-y.","journal-title":"BMC Med Res Methodol"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-023-01288-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-023-01288-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-023-01288-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T09:16:19Z","timestamp":1694250979000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-023-01288-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1288"],"URL":"https:\/\/doi.org\/10.1007\/s40273-023-01288-1","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,15]]},"assertion":[{"value":"25 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by Otsuka Pharmaceuticals Co., Ltd. The funding source had a supervising role in conducting the study and in preparing the manuscript. The open access fee was paid by Otsuka Pharmaceuticals Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Martijn Simons, Josef Paris, Elisabeth Peterse and Craig Bennison are employees of OPEN Health and report consulting fees from Otsuka during the conduct of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The datasets generated during and\/or analyzed during the current study are not publicly available due to confidentiality.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"This work reports on results of a study that was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data analyses were performed in R statistical software.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualization and design: XW, KY, YK, JP, EP, MS, CB. Data acquisition: XW, YK. Methodology: XW, KY, YK, JP, EP, CB. Formal analysis and interpretation of the data: XW, KY, YK, JP, EP, MS, CB. Validation: XW, KY, YK, JP, EP, MS, CB. Writing original draft: EP, MS, CB. Writing review and editing: XW, KY, YK, MS, CB. Critical revision of the article for important intellectual content: XW, KY, YK, JP, EP, MS, CB.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}